ChromaDex Appoints Fadi Karam as Chief Marketing Officer
ChromaDex Corp. (NASDAQ:CDXC) announced today that it has
appointed Fadi Karam as Chief Marketing Officer.
Karam has spent his career driving consumer businesses across
multiple geographies and cultures, including scaling
direct-to-consumer operations across digital, social, and
traditional marketing platforms, as well as launching and scaling
Prior to joining ChromaDex, Karam led the local brand portfolio
for Nestlé Waters North America with over $3 billion in annual
revenues. Previously, Karam was based in the Nestlé Headquarters in
Switzerland where he conceived and led a global relaunch of the
KitKat brand, and redefined the global product innovation pipeline.
He also oversaw the Nestlé confectionary strategy for Asia, Africa
and the U.S. and led the Wafer technology platform.
Karam currently serves as a Mentor at StartX, a startup
accelerator for Stanford University’s entrepreneurs. He also serves
as an advisory board member at the Chief Marketing Officer Council
and Ora Organic, and as board member at IsoThrive Inc.
Karam is a Sloan Fellow. He received an MS in Management from
Stanford University and a Bachelor’s in Computer and Communication
Engineering from Notre Dame University.
“We expect that Fadi will be an important contributor to
Chromadex and Tru Niagen® in our next phase of development,” says
ChromaDex CEO Rob Fried. “We are excited that he has decided to
join our mission of building a global brand.”
“I look forward to helping build on the excellent work already
done on this groundbreaking product, Tru Niagen®,” says Karam.
“This is a unique opportunity and challenge for which I am very
For additional information about ChromaDex, please visit
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2020, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
version on businesswire.com: https://www.businesswire.com/news/home/20210419005144/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of FP&A and Investor Relations 949-419-0288 ext.
Historical Stock Chart
From Aug 2021 to Sep 2021
Historical Stock Chart
From Sep 2020 to Sep 2021